DK1613355T3 - Ikke-konjugeret galdesyre sammen med propylgallat og/eller bha til forbedret absorbering af makromolekyler - Google Patents

Ikke-konjugeret galdesyre sammen med propylgallat og/eller bha til forbedret absorbering af makromolekyler

Info

Publication number
DK1613355T3
DK1613355T3 DK04727588.8T DK04727588T DK1613355T3 DK 1613355 T3 DK1613355 T3 DK 1613355T3 DK 04727588 T DK04727588 T DK 04727588T DK 1613355 T3 DK1613355 T3 DK 1613355T3
Authority
DK
Denmark
Prior art keywords
bha
macromolecules
conjugated
propyl gallate
improved absorption
Prior art date
Application number
DK04727588.8T
Other languages
English (en)
Inventor
Roger R C New
Original Assignee
Axcess Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcess Ltd filed Critical Axcess Ltd
Application granted granted Critical
Publication of DK1613355T3 publication Critical patent/DK1613355T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04727588.8T 2003-04-15 2004-04-15 Ikke-konjugeret galdesyre sammen med propylgallat og/eller bha til forbedret absorbering af makromolekyler DK1613355T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308734.3A GB0308734D0 (en) 2003-04-15 2003-04-15 Uptake of macromolecules
PCT/GB2004/001651 WO2004091667A1 (en) 2003-04-15 2004-04-15 Uptake of macromolecules

Publications (1)

Publication Number Publication Date
DK1613355T3 true DK1613355T3 (da) 2013-01-02

Family

ID=9956848

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04727588.8T DK1613355T3 (da) 2003-04-15 2004-04-15 Ikke-konjugeret galdesyre sammen med propylgallat og/eller bha til forbedret absorbering af makromolekyler

Country Status (19)

Country Link
US (1) US8314058B2 (da)
EP (1) EP1613355B1 (da)
JP (1) JP5047611B2 (da)
KR (1) KR101135784B1 (da)
CN (1) CN100506280C (da)
AU (1) AU2004229217B2 (da)
BR (1) BRPI0409413B8 (da)
CA (1) CA2522146C (da)
CY (1) CY1113461T1 (da)
DK (1) DK1613355T3 (da)
ES (1) ES2394640T3 (da)
GB (1) GB0308734D0 (da)
NZ (1) NZ543172A (da)
PL (1) PL1613355T3 (da)
PT (1) PT1613355E (da)
RU (1) RU2349344C2 (da)
SI (1) SI1613355T1 (da)
WO (1) WO2004091667A1 (da)
ZA (1) ZA200508344B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308732D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
GB0308734D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
GB0603252D0 (en) * 2006-02-17 2006-03-29 Axcess Ltd Dissolution aids for oral peptide delivery
WO2008132731A2 (en) * 2007-04-26 2008-11-06 Oramed Pharmaceuticals, Inc Methods and compositions for rectal administration of insulin
JP5740689B2 (ja) 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
GB0817969D0 (en) * 2008-10-01 2008-11-05 Axcess Ltd Pharmaceutical composition
RU2639483C2 (ru) 2012-03-19 2017-12-21 Сидара Терапьютикс, Инк. Режимы дозирования для соединений класса эхинокандинов
JP5877935B2 (ja) 2012-10-17 2016-03-08 メチレーション・サイエンシーズ・インターナショナル・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティＭｅｔｈｙｌａｔｉｏｎ Ｓｃｉｅｎｃｅｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｓｒｌ Ｓ−アデノシルメチオニンおよび没食子酸エステルを含む組成物
CN111655338A (zh) 2017-10-31 2020-09-11 免疫医疗有限公司 Glp-1肽类似物的口服递送
WO2021148990A1 (en) * 2020-01-23 2021-07-29 Axcess Limited Cellular uptake
WO2022114908A1 (ko) * 2020-11-27 2022-06-02 (주)디앤디파마텍 비오틴 모이어티, 지방산 모이어티 또는 이의 조합이 결합된 생리활성 물질 접합체의 경구 제형
AU2022209467A1 (en) * 2021-01-22 2023-09-07 Axcess (UK) Ltd Edta and egta for use in preserving the integrity of therapeutic compounds
WO2023038450A1 (ko) * 2021-09-07 2023-03-16 (주)디앤디파마텍 거대 생리활성 물질 및 부형제를 포함하는 약학 조성물
GB2625490A (en) * 2021-01-27 2024-06-19 D&D Pharmatech Inc Pharmaceutical composition comprising large physiologically active substance and excipient
KR102412437B1 (ko) 2022-03-10 2022-06-23 주식회사 보은기계 선택적 시공이 가능한 수로시스템
WO2024238657A2 (en) 2023-05-15 2024-11-21 Bonafide Health, Llc Sleep-improving compositions and methods of use

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB354184A (en) 1929-04-30 1931-07-29 Pharmagans Pharmaceutisches In An improved process for the production of hormone preparations
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
JPS5257313A (en) 1975-11-07 1977-05-11 Yamanouchi Pharmaceut Co Ltd Manufacture of micellar insuline emulsion preparations
JPS56138168A (en) * 1980-03-31 1981-10-28 Teijin Ltd Movel active vitamin d3 derivative composition
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS61267528A (ja) 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
US4760059A (en) * 1985-08-05 1988-07-26 Hoffmann-La Roche Inc. Rectal dosage form
IE59934B1 (en) 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
US4789660A (en) 1987-09-10 1988-12-06 American Home Products Corporation Insulin administration using methyl and propyl paraben
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
IT1251685B (it) 1991-10-11 1995-05-19 Isf Spa Composizioni farmaceutiche contenenti una calcitonina
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5849704A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
JPH05246846A (ja) 1992-03-03 1993-09-24 Taiyo Kagaku Co Ltd 蛋白質の消化促進組成物
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
CA2224227A1 (en) 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
WO1997021448A1 (en) * 1995-12-13 1997-06-19 Dullatur Limited A calcitonin preparation
CA2198966C (en) 1996-03-04 2011-06-21 Yuji Suzuki Method for cleaving chimeric protein using processing enzyme
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
GB9613858D0 (en) 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
US5912240A (en) 1997-04-10 1999-06-15 Loria; Roger M. 5-androstene 3β, 17α diol as an inhibitor of tumor growth
PT948965E (pt) * 1997-07-11 2004-08-31 Toray Industries Composicoes medicinais estaveis contendo um derivado de 4,5-epoximorfinano
US5962522A (en) 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
EP1049486A4 (en) 1997-12-05 2006-01-04 Lilly Co Eli GLP-1 FORMULATIONS
WO2000022909A2 (en) * 1998-10-19 2000-04-27 Biotech Australia Pty. Limited Systems for oral delivery
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DE60001667T2 (de) 2000-03-31 2004-01-29 Council Scient Ind Res Getreidenahrungsmittel mit hohem nährwert
JP2003532691A (ja) 2000-05-05 2003-11-05 ノボ ノルディスク アクティーゼルスカブ 重症疾患神経障害
ES2292496T3 (es) 2000-09-18 2008-03-16 Rpg Life Sciences Limited Formulacion autoemulsionable con elevada actividad inmunosupresora y bioabsorbente.
GB2368792A (en) * 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6951655B2 (en) 2001-10-11 2005-10-04 Imi Biomed, Inc. Pro-micelle pharmaceutical compositions
CA2471081A1 (en) 2001-12-19 2003-07-03 Alza Corporation Formulation & dosage form for the controlled delivery of therapeutic agents
GB0206792D0 (en) 2002-03-22 2002-05-01 Leuven K U Res & Dev Normoglycemia
GB0308734D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers

Also Published As

Publication number Publication date
KR20060021293A (ko) 2006-03-07
SI1613355T1 (sl) 2013-01-31
BRPI0409413B8 (pt) 2021-05-25
BRPI0409413B1 (pt) 2017-05-02
CA2522146C (en) 2012-06-12
JP2006523663A (ja) 2006-10-19
ZA200508344B (en) 2007-12-27
US20060122097A1 (en) 2006-06-08
AU2004229217B2 (en) 2010-03-25
RU2005135428A (ru) 2006-06-10
AU2004229217A1 (en) 2004-10-28
BRPI0409413A (pt) 2006-04-25
CA2522146A1 (en) 2005-10-13
PL1613355T3 (pl) 2013-09-30
EP1613355A1 (en) 2006-01-11
NZ543172A (en) 2009-05-31
CY1113461T1 (el) 2016-06-22
ES2394640T3 (es) 2013-02-04
JP5047611B2 (ja) 2012-10-10
HK1078277A1 (en) 2006-03-10
KR101135784B1 (ko) 2012-04-16
WO2004091667A1 (en) 2004-10-28
US8314058B2 (en) 2012-11-20
PT1613355E (pt) 2012-12-26
RU2349344C2 (ru) 2009-03-20
CN100506280C (zh) 2009-07-01
GB0308734D0 (en) 2003-05-21
EP1613355B1 (en) 2012-09-19
CN1805759A (zh) 2006-07-19

Similar Documents

Publication Publication Date Title
DK1613355T3 (da) Ikke-konjugeret galdesyre sammen med propylgallat og/eller bha til forbedret absorbering af makromolekyler
DE602004002011D1 (de) Turbomaschinenschaufel mit vermindertem Gewicht und deren Herstellungsweise
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK1651839T3 (da) Afstands- og sprossestykker til isolering af glasenheder
IS7701A (is) Arípíprazól samsett lyfjaform og aðferð
DK1968429T3 (da) Fremgangsmåde og system til stabilisering af sensorer
DE502005009089D1 (de) 1-methyl-3-trifluormethyl-pyrazol-4-carbonsäure-(ortho-phenyl)-anilide und ihre verwendung als fungizid
DE602004004267D1 (de) Formtrennmittelzusammensetzung und verfahren damit
EP1701731A4 (en) GLP-1 (9-36) METHOD AND COMPOSITIONS
DK1974017T3 (da) Midler og fremgangsmåder til at påvirke stabiliteten af antistof producerende celler
DK2308900T3 (da) Immunogene sammensætninger og fremgangsmåder til anvendelse
FI20040351L (fi) Mittausmenetelmä ja -järjestely
ITMO20020180A0 (it) Metodo di fabbricazione di serramenti in legno e alluminio, o pvc o altro materiale, e serramenti ottenuti
DK1874557T3 (da) Identitetsdokument og fremgangsmåde til fremstilling deraf
DK1562918T3 (da) Substituerede benzoxazinoner og anvendelser deraf
NO20052266D0 (no) Dunleks rustfritt stal og fremstillingsmetode derav
DK1765376T3 (da) Topiske sammensætninger og anvendelse deraf til behandling af epitel-relaterede tilstande
DE602005009988D1 (de) Härtbare Zusammensetzung und deren Verwendung
DK1754960T3 (da) Forglasningselement og fremgangsmåde til fremstilling heraf
ATE517098T1 (de) Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren
DK1867332T3 (da) Farmaceutisk sammensætning og fremgangsmåde under anvendelse af et antimykotisk middel i kombination
DK1810013T3 (da) Fugtighedssensor og fremgangsmåde til fremstilling af samme
EP1847630A4 (en) HIGHLY CARBURATED / VOLTAGE-FREE REMOVED COMPONENT AND METHOD OF MANUFACTURING THEREOF
DK1882054T3 (da) Korrosionsbeskyttelsesanordning og fremgangsmåde
DE602006019849D1 (de) Proteinspaltungsverfahren und verwendung davon